Buy & Sell Illumina, Inc. (ILMN) – Illumina, Inc. Price Today
Key Stats
- $24.21BMarket Cap
- HealthSector
- -10.51%3M Drawdown
- $25.60BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 85 daysTypical Hold Time
Illumina, Inc. (ILMN) is currently valued at a market capitalization of $24.21B, with an enterprise value of $25.60B. Over the past 52 weeks, Illumina, Inc. has traded between a low of $86.93 and a high of $170.93, highlighting its annual price range. Over the past three months, Illumina, Inc. has recorded a drawdown of -10.51%, reflecting recent price volatility. On average, investors hold Illumina, Inc. for approximately 85 days, indicating typical investor behavior on the platform.
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Most Recent News
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...
Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...